Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and TAS-102 in Metastatic Colorectal Cancer
NCT04868773Phase 1Completed
- Sponsor
- University of California, Irvine
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in colorectal cancer (CRC), sponsored by University of California, Irvine. Primary endpoints: Dose Limiting Toxicity at 1 year and Recommended Phase 2 Dose at 1 year. Started Jul 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04868773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868773.